新型疗法和即将到来的临床试验针对心血管疾病的炎症
Nicola Potere1, Aldo Bonaventura2, Antonio Abbate3
1Department of Medicine and Ageing Sciences, "G. d'Annunzio" University of Chieti-Pescara, Italy (N.P.).
Arteriosclerosis, thrombosis, and vascular biology
|October 10, 2024
概括
系统性炎症驱动心血管疾病 (CVD) 的发展. 准炎症途径,如NLRP3炎症酶/互白素-1β,对心血管疾病治疗具有前景,现在被批准用于二次预防的菌素.
科学领域:
- 心脏免疫学心脏免疫学
- 炎症和心血管疾病.
- 药理干预药理干预
背景情况:
- 系统性炎症是心血管疾病 (CVD) 发病和进展的关键驱动因素.
- 尽管取得了进展,但对心血管疾病抗炎疗法的临床转化仍受不确定的信号,安全问题和患者选择挑战所限制.
研究的目的:
- 审查炎症在心血管疾病中的作用以及抗炎治疗策略的进展.
- 讨论已完成和即将进行的针对心血管疾病炎症的临床试验.
- 突出心脏免疫学领域的挑战和未来方向.
主要方法:
- 对心血管疾病的抗炎干预措施的临床前证据和临床试验数据的审查.
- 专注于NLRP3炎症酶/IL-1β通路以及诸如canakinumab和colchicine等药物.
- 讨论重新使用和新型抗炎化合物.
主要成果:
- 随机试验证实了canakinumab和colchicine在二次心血管预防中的有效性,验证了NLRP3炎症酶/IL-1β通路.
- 科尔奇辛已获得FDA批准用于二次心血管预防.
- 抗炎药物用于心肌炎和心周炎,正在研究更广泛的心血管疾病应用.
结论:
- 针对特定的炎症途径,特别是NLRP3炎症酶/IL-1β,是动脉样硬化心血管疾病的验证治疗策略.
- 进一步的研究和临床试验对于开发和优化各种心血管疾病的抗炎疗法至关重要.
- 心血管免疫学领域为管理心血管疾病的新疗法提供了巨大的潜力.
相关概念视频
01:26Atherosclerosis III: Management
2
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
2
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
117
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
117
01:19Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers
61
Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
61
01:29Inflammatory Bowel Disease IV: Pharmacological Management
118
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
118
01:14Myocarditis III: Medical Management
2
Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
2
01:25Antianginal Drugs: Calcium Channel Blockers and Ranolazine
462
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
462